- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05149872
The Breath-2 Trial
February 7, 2025 updated by: Martijn Boon, Leiden University Medical Center
Recovery of Carotid Body Function After Full Recovery Neuromuscular Block
This is a randomized, cross over, experimental trial in which carotid body function will be evaluated in 35 healthy subjects during partial muscle relaxation and after recovery from muscle relaxation
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
35
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Zuid Holland
-
Leiden, Zuid Holland, Netherlands, 2333ZA
- Leiden Medical University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
* age > 18 years
Exclusion Criteria:
- BMI index > 30 kg/m2
- Known or suspected neuromuscular disorders impairing neuromuscular function;
- Allergies to muscle relaxants, anesthetics or narcotics;
- A (family) history of malignant hyperthermia or any other muscle disease;
- Any neurological or psychiatric illness (including a history of anxiety).
- ASA class 3 or higher
- Gastro-oesophageal regurgitation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: spontaneous recovery
Spontaneous recovery
|
Rocuronium will be used to induce partial paralysis
|
|
Other: reversal with sugammadex 2 mg/kg
|
Rocuronium will be used to induce partial paralysis
Sugamamdex will be used to reverse muscle relaxation
|
|
Other: reversal with sugammadex 4 mg/kg
|
Rocuronium will be used to induce partial paralysis
Sugamamdex will be used to reverse muscle relaxation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Carotid body function after full recovery of neuromuscular block
Time Frame: 40 minutes after full recovery of neuromuscular block
|
Carotid body function will be determined by measuring acute hypoxic ventilatory response
|
40 minutes after full recovery of neuromuscular block
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Carotid body function at symptomatic neuromuscular block
Time Frame: 5 minutes after stable partial neuromuscular block
|
Carotid body function will be determined by measuring acute hypoxic ventilatory response
|
5 minutes after stable partial neuromuscular block
|
|
Carotid body function at full recovery of NMB symptoms
Time Frame: 0 minutes after full recovery of neuromuscular block symptoms
|
Carotid body function will be determined by measuring acute hypoxic ventilatory response
|
0 minutes after full recovery of neuromuscular block symptoms
|
|
Carotid body function after full recovery of neuromuscular block
Time Frame: 20 minutes after full recovery of neuromuscular block symptoms
|
Carotid body function will be determined by measuring acute hypoxic ventilatory response
|
20 minutes after full recovery of neuromuscular block symptoms
|
|
Carotid body function after full recovery of neuromuscular block
Time Frame: 40 minutes after full recovery of neuromuscular block symptoms
|
Carotid body function will be determined by measuring acute hypoxic ventilatory response
|
40 minutes after full recovery of neuromuscular block symptoms
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 15, 2022
Primary Completion (Actual)
November 1, 2022
Study Completion (Actual)
April 1, 2023
Study Registration Dates
First Submitted
November 9, 2021
First Submitted That Met QC Criteria
December 7, 2021
First Posted (Actual)
December 8, 2021
Study Record Updates
Last Update Posted (Actual)
March 25, 2025
Last Update Submitted That Met QC Criteria
February 7, 2025
Last Verified
October 1, 2024
More Information
Terms related to this study
Other Study ID Numbers
- P21.083
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Chemosensitivity
-
Dana-Farber Cancer InstitutePaxman Coolers LimitedRecruitingChemotherapy-induced Peripheral Neuropathy | CIPN - Chemotherapy-Induced Peripheral Neuropathy | Taxane-Induced Peripheral NeuropathyUnited States
-
Dana-Farber Cancer InstituteRecruitingNeuropathy | Peripheral Neuropathies | Peripheral Neuropathy Due to Chemotherapy | Chemotherapy Induced Peripheral Neuropathy (CIPN)United States
-
Second Affiliated Hospital, School of Medicine,...Not yet recruitingChemotherapy-Induced Peripheral Neuropathy | Paclitaxel-Induced Peripheral Neuropathy | Refractory Chemotherapy-Induced Peripheral Neuropathy
-
Arash Asher, MDVoxxLifeCompletedNeuropathy | Chemotherapy-induced Peripheral Neuropathy | Neuropathy;PeripheralUnited States
-
University of NebraskaRecruitingPeripheral Arterial Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Peripheral Artery Occlusive DiseaseUnited States
-
University of RochesterBeth Israel Deaconess Medical CenterRecruitingIdiopathic Peripheral Neuropathy | Chemotherapy Induced Peripheral Neuropathy (CIPN) | Painful Peripheral Neuropathy | Diabetic Peripheral Neuropathic Pain (DPN)United States
-
University of Milano BicoccaRecruitingPeripheral NeuropathiesItaly
-
The University of Texas Health Science Center at...CompletedPeripheral NeuropathiesUnited States
-
University of NebraskaRecruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | Peripheral Arterial Occlusive Disease | Peripheral Artery DiseaseUnited States
-
C. R. BardCromsourceCompletedVascular Diseases, PeripheralGermany, Poland
Clinical Trials on Muscle relaxation
-
Mayo ClinicCompleted
-
Ege UniversityCompletedRestless Legs Syndrome
-
Cairo UniversityUnknownAttention Deficit Disorder With Hyperactivity
-
Johns Hopkins UniversityRecruitingAnxiety | Sleep Disturbance | Depressive Symptoms | Pruritus | Burn | Virtual Reality | Progressive Muscle Relaxation | Burn Injury | Fatigue Symptom | Chronic Pain Following Thermal Burn Injury | Non-Pharmacological InterventionsUnited States
-
Gazi UniversityCompletedProgressive Muscle Relaxation ExerciseTurkey
-
University of Health Sciences LahoreActive, not recruitingPremenstrual Syndrome-PMSPakistan
-
Istanbul University - CerrahpasaRecruitingPre-Eclampsia | Maternal Health | Virtual Reality | Relaxation | Fetal MonitoringTurkey (Türkiye)
-
Ataturk UniversityCompletedStress | Anxiety | Nursing Students | Relaxation ProgramTurkey
-
Hacettepe UniversityAnkara City Hospital BilkentRecruiting
-
Ankara Yildirim Beyazıt UniversityCompletedCoronary Artery Disease | Muscle RelaxationTurkey